PDT Partners’s Voyager Therapeutics VYGR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-22,163
Closed -$130K 847
2024
Q3
$130K Sell
22,163
-53,542
-71% -$389K 0.01% 685
2024
Q2
$599K Buy
+75,705
New +$635K 0.06% 431
2022
Q3
Sell
-10,165
Closed -$60K 1112
2022
Q2
$60K Buy
+10,165
New +$68.7K 0.01% 910
2022
Q1
Sell
-27,100
Closed -$73K 1139
2021
Q4
$73K Hold
27,100
0.01% 838
2021
Q3
$71K Sell
27,100
-9,700
-26% -$31.5K 0.01% 744
2021
Q2
$152K Sell
36,800
-52,358
-59% -$237K 0.01% 738
2021
Q1
$420K Buy
89,158
+33,841
+61% +$231K 0.03% 538
2020
Q4
$396K Buy
55,317
+10,465
+23% +$101K 0.03% 493
2020
Q3
$479K Buy
44,852
+9,686
+28% +$114K 0.03% 455
2020
Q2
$444K Buy
+35,166
New +$409K 0.03% 441
2020
Q1
Sell
-10,078
Closed -$141K 872
2019
Q4
$141K Buy
+10,078
New +$146K 0.01% 677
2018
Q4
Sell
-10,276
Closed -$194K 516
2018
Q3
$194K Sell
10,276
-109,224
-91% -$2.1M 0.01% 435
2018
Q2
$2.33M Sell
119,500
-29,100
-20% -$575K 0.09% 241
2018
Q1
$2.79M Sell
148,600
-25,800
-15% -$558K 0.09% 231
2017
Q4
$2.9M Buy
174,400
+111,113
+176% +$1.91M 0.08% 253
2017
Q3
$1.3M Buy
+63,287
New +$714K 0.04% 328

Other funds holding VYGR

PDT Partners's VYGR Position: Q4 2024 in Review

PDT Partners sold out of Voyager Therapeutics (VYGR) in Q4 2024, closing a stake of 22,163 shares — an estimated $130K sold.

PDT Partners first reported a position in VYGR in Q3 2017 and held it in 16 quarters. The position peaked at $2.9M in Q4 2017. 132 funds tracked by Wall St. Rank hold VYGR as of Q4 2024.

  • PDT Partners reported no remaining Voyager Therapeutics position as of Q4 2024 after selling out during the quarter.
  • PDT Partners sold 22,163 Voyager Therapeutics shares in Q4 2024, an estimated $130K.
  • PDT Partners first reported a position in Voyager Therapeutics in Q3 2017 and held it in 16 quarters.
  • PDT Partners's Voyager Therapeutics position peaked at $2.9M in Q4 2017.
  • 132 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2024.

Based on PDT Partners's 13F filing for Q4 2024, filed 14 Feb 2025.